ACSL4 and hepatocellular carcinoma: In the treatment of hepatocellular carcinoma, sorafenib, as an FDA-certified anticancer drug, can induce ferroptosis in the presence of ACSL4 acyl-CoA synthetase long chain family member 4 (53).